| Nesiritide | acute heart failure, in all type of patients | vs control | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amelioration of Dyspnea at 6 h | no data | | amelioration of Dyspnea at 24 h | no data | | 30-day death | no data | | Death from any cause or hospitalization for heart failure | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| NSGET (comparative trial), 2000 | nesiritide(0.015 and 0.030 microg/kg/min | usual care | acutely decompensated heart failure requiring invasive monitoring
|
| |
| Nesiritide | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amelioration of Dyspnea at 6 h | no data | | amelioration of Dyspnea at 24 h | 1.11 [1.00 1.23] | p=1.00 | 0 | 7007 | 1 | ASCEND-HF, | | 30-day death | 0.90 [0.70 1.15] | p=1.00 | 0 | 7007 | 1 | ASCEND-HF, | | Death from any cause or hospitalization for heart failure | 0.93 [0.80 1.10] | p=1.00 | 0 | 7007 | 1 | ASCEND-HF, | | hospitalisation for heart failure | 0.98 [0.81 1.20] | p=1.00 | 0 | 7007 | 1 | ASCEND-HF, | | All cause death | 0.93 [0.73 1.18] | p=1.00 | 0 | 7371 | 3 | NSGET (efficacy trial), PROACTION, ASCEND-HF, |
| Trial | Studied treatment | Control | Patients |
|---|
| NSGET (efficacy trial), 2000 | nesiritide(0.015 and 0.030 microg/kg/min | placebo | acutely decompensated heart failure requiring invasive monitoring | | PROACTION, 2003 | nesiritidefor at least 12h | placebo | patients presenting to the ED with acutely decompensated
HF and dyspnea at rest or with minimal activity | | BNP-CARDS, 2007 | nesiritide as a 0.01-µg/kg/min infusion for 48 hours | placebo | acute decompensated heart failure with moderate to severe renal insufficiency | | FUSION 2, 2008 | nesiritide (2 µg/kg bolus plus 0.01 µg/kg-per-minute infusion for four to six hours) | placebo | patients with ACC/AHA stage C/D heart failure with two recent heart-failure hospitalizations, an ejection fraction of less than 40%, and NYHA class 4 symptoms or NYHA class 3 symptoms with creatinine clearance less than 60 mL/min | | ASCEND-HF, 2011 | intravenous nesiritide for 24 hours to 7 days on top of standard therapy | matching placebo | Patients hospitalized for heart
failure (within 24 hours of hospitalization and institution of acute IV therapy for ADHF) | | VMAC (intravenous neseritide), 2002 | intravenous nesiritidefor 3 hours | placebo | acutely decompensated heart failure requiring hospitalization |
| |
| Nesiritide | | vs dobutamine | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amelioration of Dyspnea at 6 h | no data | | amelioration of Dyspnea at 24 h | no data | | 30-day death | no data | | Death from any cause or hospitalization for heart failure | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| PRECEDENT, 2002 | nesiritide(0.015 or 0.03 microg/kg/min) | Dobutamine (> or =5 microg/kg/min) | Symptomatic, Decompensated CHF |
| |
| Nesiritide | | vs nitroglycerin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amelioration of Dyspnea at 6 h | no data | | amelioration of Dyspnea at 24 h | no data | | 30-day death | no data | | Death from any cause or hospitalization for heart failure | no data | | hospitalisation for heart failure | no data | | All cause death | 1.56 [0.76 3.19] | p=1.00 | 0 | 498 | 1 | VMAC (24h), |
| Trial | Studied treatment | Control | Patients |
|---|
| VMAC (24h), 2002 | nesiritideinfusion for 24 hours | nitroglycerin | acutely decompensated heart failure requiring hospitalization |
| |
| Nesiritide | | vs standard care | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amelioration of Dyspnea at 6 h | no data | | amelioration of Dyspnea at 24 h | no data | | 30-day death | no data | | Death from any cause or hospitalization for heart failure | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| FUSION 1, 2004 | nesiritide 0.005 microg/kg/min or 0.010 microg/kg/min once weekly | standard care | outpatient with co-morbid advanced heart failure and renal insufficiency |
| |
| Levosimendan | acute heart failure, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amelioration of Dyspnea at 6 h | no data | | amelioration of Dyspnea at 24 h | no data | | 30-day death | no data | | Death from any cause or hospitalization for heart failure | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| REVIVE II, 2013 | Intravenous Levosimendan | placebo | patients with decompensated chronic heart failure | | REVIVE-I, 2003 | levosimendan 0.1–0.2 mg/kg/min | placebo | patienst with HF andsymptoms at rest | | RUSSLAN, 2002 | Levosimendan at different doses (0.1-0.4 microg x kg(-1) x min(-1)) for 6h | placebo | patients with left ventricular failure complicating acute myocardial infarction |
| |
| Levosimendan | | vs dobutamine | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amelioration of Dyspnea at 6 h | no data | | amelioration of Dyspnea at 24 h | no data | | 30-day death | no data | | Death from any cause or hospitalization for heart failure | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| SURVIVE, 2007 | Intravenous levosimendan | intravenous dobutamine | patients hospitalized with acute decompensated heart failure who required inotropic support | | CASINO, 0 | Levosimendan 16 mg/kg þ 0.2 mg/kg/min | Dobutamine (10 mg/kg/min) and placebo | patients withdecompensatedlow-output HF | | LIDO, 2002 | Levosimendan | Dobutamine | patients with low-output heart failure |
| |
| Serelaxin | acute heart failure, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| death or hospitalization | no data | | Cardiovascular death or hospital admission for CHF | no data | | heart failure death | no data | | hospitalisation for cardiovascular causes | no data | | CV death, MI hospitalization for HF | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Pre-RELAX-AHF, 2009 | intravenous relaxin for 48 hours: 10µg/kg daily, 30µg/kg daily, 100µg/kg daily, 250µg/kg daily | placebo | Patients hospitalized with acute heart failure | | RELAX-AHF, 2013 | 48-h intravenous infusions of placebo or serelaxin (30 ìg/kg per day) within 16 h from presentation | placebo (on top stnadard care) | patients admitted to hospital for acute heart failure |
| |
| Rolofylline | acute heart failure, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| PROTECT, 2010 | daily intravenous rolofylline (30 mg) for up to 3 days | placebo | patients hospitalized for acute heart failure with impaired renal function |
| |
